Related Experiment Video

Updated: Dec 18, 2025

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome
04:45

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

2.7K

Is Albumin Predictor of Mortality in COVID-19?

Francesco Violi1, Roberto Cangemi2, Giulio Francesco Romiti2

  • 1I Clinica Medica, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Departments of Sapienza University of Rome, Rome, Italy.

Antioxidants & Redox Signaling
|June 12, 2020
PubMed

Insights

Low human serum albumin (HSA) levels are linked to increased mortality risk in COVID-19 patients. HSA analysis may help identify high-risk individuals for better COVID-19 patient management.

Area of Science:

  • Biochemistry
  • Immunology
  • Critical Care Medicine

Background:

  • Human serum albumin (HSA) possesses antioxidant properties, but its role in COVID-19 outcomes was previously unexamined.
  • COVID-19 is a pandemic characterized by significant mortality, necessitating identification of prognostic markers.
  • This study investigated the association between HSA levels and mortality in hospitalized COVID-19 patients.

Discussion:

  • Nonsurvivors exhibited higher rates of ICU admission, comorbidities (COPD, heart failure), and elevated inflammatory markers (D-dimer, hs-CRP) compared to survivors.
  • Lower serum albumin levels were a significant predictor of mortality in COVID-19 patients.
  • Albumin levels independently predicted mortality, even after adjusting for age, gender, ICU status, comorbidities, and hs-CRP.

Key Insights:

  • Albumin levels (HR: 0.38, p<0.001) and age (HR: 1.03, p=0.001) were independent predictors of mortality in COVID-19.
  • Hypoalbuminemia may serve as a prognostic indicator for mortality in COVID-19.
  • HSA levels offer potential as a biomarker for risk stratification in COVID-19 patients.

Outlook:

  • Further research is warranted to elucidate the precise mechanisms linking HSA to COVID-19 mortality.
  • HSA level monitoring could aid clinicians in identifying high-risk COVID-19 patients.
  • This finding may inform therapeutic strategies aimed at improving outcomes for critically ill COVID-19 patients.

Keywords:
COVID-19albuminmortality

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.0K
Assessment of Kidney Function in Mouse Models of Glomerular Disease09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

18.4K

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
388
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
200
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
233
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
441
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
647
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.1K